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Identifying and Validating Tankyrase Binders 
and Substrates: A Candidate Approach
Katie Pollock, Michael Ranes, Ian Collins, and Sebastian Guettler
Abstract
The poly(ADP-ribose)polymerase (PARP) enzyme tankyrase (TNKS/ARTD5, TNKS2/ARTD6) uses its 
ankyrin repeat clusters (ARCs) to recognize degenerate peptide motifs in a wide range of proteins, thereby 
recruiting such proteins and their complexes for scaffolding and/or poly(ADP-ribosyl)ation. Here, we 
provide guidance for predicting putative tankyrase-binding motifs, based on the previously delineated 
peptide sequence rules and existing structural information. We present a general method for the expression 
and purification of tankyrase ARCs from Escherichia coli and outline a fluorescence polarization assay to 
quantitatively assess direct ARC–TBM peptide interactions. We provide a basic protocol for evaluating 
binding and poly(ADP-ribosyl)ation of full-length candidate interacting proteins by full-length tankyrase 
in mammalian cells.
Key words Tankyrase, PARP, Poly(ADP-ribosyl)ation, Tankyrase-binding peptide motif, Enzyme–
substrate relationships, Protein-protein interactions, Protein expression, Protein purification, 
Fluorescence polarization (FP), Structural biology
1 Introduction
Poly(ADP-ribosyl)ation (PARylation) constitutes a striking post-
translational modification (PTM) catalyzed by poly(ADP-ribose)
polymerase (PARP) enzymes, which serially transfer ADP-ribose 
from NAD+ onto substrate proteins [1]. The resulting long, strongly 
negatively charged PAR chains provide attachment sites for proteins 
endowed with PAR-binding modules or directly affect substrate 
function [2]. PAR can thus act as a scaffolding component as well 
as a regulatory PTM. PARylation is most commonly associated with 
nuclear events such as gene regulation and DNA damage repair, but 
PAR is found in both the nucleus and the cytoplasm [1, 3]. The 
PARP tankyrase, of which there are two human paralogs (TNKS/
ARTD5, TNKS2/ARTD6, see Fig. 1a), contributes to both the 
nuclear and cytoplasmic pools of PAR [4, 5]. The biological roles of 
the two tankyrases are largely redundant [6], pointing to shared 
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Fig. 1 Substrate binding by tankyrase. (a) Domain organization of human tankyrase and tankyrase 2 (modified 
from [31]). (b) and (c) Examples for ARC–TBM interactions studied by X-ray crystallography. (b) Human TNKS2 
ARC4 is shown in surface representation with bound TBM peptides from 3BP2 and MCL1 shown in stick rep-
resentation with the core TBM octapeptide colored purple and orange, respectively, and by heteroatom. TBM 
amino acid positions (1–8) and sequences shown. The figure was generated by superimposing the ARCs of the 
ARC4-3BP2 and ARC4- MCL1 crystal structures (PDB accession codes 3TWR and 3TWU, respectively) onto 
each other and showing ARC4 of the former [7]. The colored surface areas represent different contact areas, 
as indicated, that mediate binding of the TBM peptides (Modified from [7] with permission from Elsevier/Cell 
Press). (c) ARC2 (from ARC2–3) of murine Tnks bound by the N-terminus of murine Axin1 (PDB accession code 
3UTM), which contains two TBMs [11]. Each TBM binds one copy each of ARC2 in a dimeric ARC2-3 assembly. 
The figure was generated by superimposing the two ARC2-3 copies onto each other; the surface of ARC2 
bound by the first TBM is shown. TBMs are shown and labeled as in (b). The first TBM, shown in magenta, 
consists of a continuous stretch of eight amino acids. In the second TBM, shown in green, the Arg at position 
1 is followed by a seven-amino-acid insertion (positions +1 to +7), as indicated in the sequences shown. The 
peptide insertion forms a loop. (d) TBM sequence rules represented by a sequence logo. (Reprinted from [7] 
with permission from Elsevier/Cell Press.) (e) Sequence alignment of known example TBMs ([7] and references 
therein, [11, 22, 23, 37–39]), colored by identity with conservation graph, generated with ClustalX and Jalview 
[40, 41]. UniProt IDs are indicated [24]. The asterisk indicates insertion sequences in AXIN1 and AXIN2. The 
TBMs of 3BP2, TRF1 (TERF1_HUMAN), and MERIT40 (BABA1_HUMAN), studied as model TBMs here, are 
highlighted
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molecular mechanisms. The  recruitment of tankyrase to different 
protein complexes associated with specific cellular processes and 
situated at different subcellular locations defines its diverse func-
tions. All tankyrase binders characterized to date bear a tankyrase-
binding motif (TBM), which in its simplest form consists of six to 
eight consecutive amino acids [4, 7, 8]. TBMs are recognized by 
tankyrase’s ankyrin repeat clusters (ARCs) [7, 9, 10]. Out of the 
five ARCs, the central one (ARC3) is devoid of a known peptide-
binding function while the other four (ARCs 1, 2, 4, and 5) each 
feature a highly conserved peptide-binding pocket with similar 
specificities [7, 10] (Fig. 1a). Given four peptide-binding ARCs, 
tankyrase recognizes its binders multivalently.
The TBM has been characterized extensively and a consensus 
sequence of R-x-x-[small hydrophobic or G]-[D/E]-G-[no 
P]-[D/E] identified through positional scanning and evaluation 
of known TBMs [7] (Fig. 1d and e). Paired with structural infor-
mation from ARC–peptide complexes [7, 11–13], these 
“sequence rules” provide a valuable tool for identifying tankyrase 
binders/substrates. Fig. 1b–e gives examples for X-ray crystal 
structures describing TBM-ARC interactions, summarize the 
experimentally derived TBM sequence rules, and list known 
TBMs. Within the motif, the Arg residue at position 1, bound in 
an extensive “Arg cradle,” is essential, as is Gly at position 6, 
owing to its unique geometry that is adopted when the residue is 
sandwiched between two aromatic side chains in the ARC 
(Fig. 1b, d). At positions 2 and 3, where side chains point away 
from the ARC, a wide range of amino acids is tolerated. At posi-
tion 4, a small and/or hydrophobic residue binds a tight hydro-
phobic sub-pocket. Gly, Pro, Ala, and Cys (in this order of 
preference) have been found suitable by positional scanning [7], 
and known TBMs mostly feature Pro and Gly, followed by Ala, 
Val, Leu, and Cys (Fig. 1e). At position 5, Asp is clearly pre-
ferred, with Glu ranked second, but Val, Gln, Tyr, Ile, and Cys 
were all allowed in positional scanning experiments (Fig. 1b, d) 
[7]. In line with these observations, Asp and Glu are found at 
position 5 in the vast majority of known TBMs, followed by Gln, 
Pro, Ile, and Val (Fig. 1e). Positions 7 and 8 tolerate a wide range 
of amino acids, with the exception of Pro at position 7, where 
Pro causes an unfavorable distortion of the peptide backbone 
(Fig. 1d). At position 8, Asp and Glu are most favored, owing to 
an electrostatic contact with the ARC, and can balance out the 
negative contribution made by suboptimal residues at other posi-
tions (Fig. 1b, d) [7]. Recent structural and biophysical studies 
suggest that the spatial organization of the five ARCs and the 
positioning of multiple TBMs within a subset of tankyrase bind-
ers encode another determinant of tankyrase binding [13].
Among the tankyrase–substrate relationships most extensively 
studied to date are those with AXIN (axis inhibition protein, 
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AXIN1, AXIN2), scaffolding proteins involved in Wnt signaling 
[11, 14], the telomeric protein TRF1 (telomeric repeat-binding 
factor 1, official gene name TERF1) [12, 15], and the signaling 
adaptor protein 3BP2 (SH3 domain-binding protein 2, official 
gene name SH3BP2) [7, 16]. Many more tankyrase binders/sub-
strates have been identified, and the list of known interactors keeps 
expanding [5]. An in silico prediction of tankyrase binders gives 
reason to anticipate a broad involvement of tankyrase in a wide 
range of biological functions [7]. To understand the complex bio-
logical roles of tankyrase, also in light of the considerable interest in 
tankyrase as a potential therapeutic target [5, 17], we require 
insights into the complement of tankyrase-binding proteins in the 
proteome.
Here, we outline a hierarchical three-step candidate approach 
for identifying tankyrase binders and substrates, providing further 
experimental detail on the method reported previously [7]. Step 1 
constitutes TBM prediction, step 2 the evaluation of TBMs as 
direct ARC binders by fluorescence polarization (FP), and step 3 
the validation of tankyrase binding and tankyrase-dependent 
PARylation in the full-length protein context. We chose two model 
proteins: the first identified tankyrase binder, TRF1 [15], and a 
novel tankyrase binder, MERIT40 (Mediator of RAP80 interac-
tions and targeting subunit of 40 kDa, official gene name BABAM1), 
which was identified by the approach presented here [7]. The TBM 
from 3BP2 serves as an additional example in the FP assay [7]. As 
part of step 2, we present a general method for the expression and 
purification of TNKS and TNKS2 ARCs from Escherichia coli 
Table 1 
Human tankyrase (TNKS/TNKS2) ARC constructs for biophysical assays. 
The proteins include a non-native, vector-derived GAMGS sequence at the 
N-terminus that is retained upon cleavage of the affinity tag [7]
ARC construct Construct boundaries Molecular weight (kDa)
TNKS ARC1–5 178–958 85.0
TNKS ARC1 178–336 17.2
TNKS ARC2–3 331–645 34.7
TNKS ARC4 646–807 18.0
TNKS ARC5 799–958 17.5
TNKS2 ARC1–5 20–800 85.3
TNKS2 ARC1 20–178 17.7
TNKS2 ARC2–3 173–487 35.3
TNKS2 ARC4 488–649 17.9
TNKS2 ARC5 641–800 17.3
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(Table 1). ARCs 1, 4, and 5 can be produced as individual domains. 
ARCs 2 and 3 are insoluble when produced independently; how-
ever, they can be produced as a double ARC2-3 construct. 
Moreover, the entire tankyrase N-termini with all five ARCs can be 
generated [7, 13]. Proteins are expressed with a cleavable N-terminal 
His6-GST tag, which enables simple affinity purification, minimally 
followed by size exclusion chromatography upon tag removal. The 
subsequent FP assay uses a candidate TBM peptide, synthesized 
with a fluorescent label such as fluorescein, to directly measure the 
binding affinity to a tankyrase ARC or a set of ARCs. In this assay, 
the fluorescent peptide probe is excited by polarized light. The light 
emitted by an unbound probe loses most of its polarization due to 
its rapid motion in solution. When bound to an ARC, movement of 
the peptide is slowed down and a high degree of polarization 
retained in the emitted light. Titration of tankyrase ARCs at a con-
stant probe concentration allows the dissociation constant (Kd) to 
be determined [7, 18–20]. Upon confirmation of the isolated 
TBM, further validation of the candidate tankyrase binder requires 
an assessment of tankyrase binding and substrate PARylation using 
full-length proteins (step 3). We present details for a straightfor-
ward assay based on co-expression in HEK293T cells, co-immuno-
precipitation and the detection of PAR in the immunoprecipitates, 
using PAR-binding antibodies [7].
2 Materials
Unless the supplier is explicitly mentioned, chemicals are typically 
obtained from Sigma-Aldrich.
 1. Inducible bacterial expression constructs for affinity-tagged 
tankyrase ARCs (TNKS: NM_003747.2; TNKS2: 
NM_025235.2; see Table 1 for construct details; see Note 1).
 2. BL21-CodonPlus (DE3)-RIL E. coli chemically competent 
cells (Agilent Technologies) (see Note 2).
 3. “Lysogeny Broth” (LB) agar plates, supplemented with kana-
mycin (50 μg/mL) and chloramphenicol (34 μg/mL).
 4. LB medium (100 mL for overnight starter culture).
 5. “Terrific Broth” (TB) medium (4–8 L for large-scale expression).
 6. 1000× stock solutions of antibiotics: 50 mg/mL kanamycin 
(in H2O) and 34 mg/mL chloramphenicol (in isopropanol).
 7. Shaking incubators capable of a temperature range of at least 
18–37 °C.
 8. Erlenmeyer flasks (250 mL) for pre-cultures, baffled Erlenmeyer 
flasks (2 L) for large-scale expression.
 9. Isopropyl β-d-1-thiogalactopyranoside (IPTG, 1 M stock 
solution)
2.1 Protein 
Expression
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 10. Refrigerated centrifuge for harvesting large volumes of bacte-
rial cultures (4000 × g, e.g., Beckman Coulter Avanti J-26XP 
with JLA 8.1000 rotor).
 11. Liquid nitrogen bath.
 12. 50 mL Falcon tubes or plastic film with thermal sealer for stor-
age of bacterial pellets.
 1. Protease inhibitors, such as Pierce protease inhibitor tablets, 
EDTA-free (Thermo Fisher Scientific).
 2. Lysozyme, 40 mg/mL stock.
 3. Sonicator fitted with a large probe or homogenizer capable of 
breaking bacterial cells.
 4. Ultra-filtered H2O.
 5. Cell lysis buffer: 50 mM Tris–HCl pH 7.5, 500 mM NaCl, 
5 mM β-mercaptoethanol. Add protease inhibitor tablets 
and lysozyme (100 μg/mL final concentration) immediately 
before use.
 6. Refrigerated centrifuge for removing insoluble lysate fraction 
(30,000 × g, e.g., Beckman Coulter Allegra 64R with F0650 
rotor).
 7. 5.0 μm syringe filter units.
 8. 5 mL HisTrap HP Ni2+ affinity column (GE Healthcare, 
see Note 3).
 9. Peristaltic pump.
 10. Vacuum pump and bottle filters (0.22 μm) for filtering and 
degassing buffers.
 11. Buffer A for Ni2+ affinity column: 50 mM Tris–HCl pH 7.5, 
500 mM NaCl, 5 mM β-mercaptoethanol, 10 mM imidazole 
pH 7.5—filtered and degassed.
 12. Buffer B for Ni2+ affinity column: 50 mM Tris pH 7.5, 500 mM 
NaCl, 5 mM β-mercaptoethanol, 250 mM imidazole pH 7.5—
filtered and degassed.
 13. FPLC system with buffer gradient capabilities, UV absorbance 
detector and fraction collector (e.g., ÄKTA Purifier, GE 
Healthcare).
 14. 5 mL HiTrap Q HP column (GE Healthcare).
 15. Buffer A for Q column: 50 mM Tris–HCl pH 7.5, 100 mM 
NaCl, 5 mM β-mercaptoethanol—filtered and degassed.
 16. Buffer B for Q column: 50 mM Tris–HCl pH 7.5, 1.5 M 
NaCl, 5 mM β-mercaptoethanol—filtered and degassed.
 17. Dialysis buffer: 50 mM Tris–HCl pH 7.5, 100 mM NaCl, 
5 mM β-mercaptoethanol (see Note 11).
 18. Dialysis tubing, 3500 Da molecular weight cutoff (MWCO).
 19. Dialysis tubing clips.
2.2 Protein 
Purification
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 20. 2 L beaker, magnetic stirrer plate, stirrer bar.
 21. TEV protease, 5 mg/mL stock.
 22. 15 mL spin protein concentrator, 3000 Da MWCO for single- 
ARC constructs, 10,000 Da MWCO for double-ARC con-
structs, 30,000 Da MWCO for ARC1-5 constructs.
 23. Refrigerated centrifuge for concentrating protein (3200 × g, 
e.g., Beckmann Coulter Allegra X12-R centrifuge with SX4750 
swinging bucket rotor).
 24. Refrigerated centrifuge for removing precipitate prior to size 
exclusion chromatography (18,000 × g, e.g., Eppendorf 
5417R with F45-30-11 rotor).
 25. HiLoad 16/600 Superdex 75 or 200 pg size exclusion column 
(GE Healthcare, see Note 4).
 26. Tris(2-carboxyethyl)phosphine (TCEP), 0.5 M stock 
(see Note 5).
 27. Size exclusion buffer: 25 mM HEPES-NaOH pH 7.5, 100 mM 
NaCl, 2 mM TCEP—filtered and degassed (see Notes 6 and 11).
 28. 96-deep-well blocks for fraction collection, or fraction collec-
tor tubes (depending on the format of the fraction collector).
 29. UV spectrophotometer.
 30. 4× SDS sample buffer.
 31. 15% polyacrylamide gels for SDS-PAGE.
 32. Protein standard for SDS-PAGE.
 33. Coomassie stain for SDS-PAGE gels.
 34. 15 mL and 50 mL Falcon tubes.
 35. Thin-walled individual 0.2 mL PCR tubes for flash-freezing 
protein aliquots.
 36. Liquid nitrogen bath.
 1. Plate reader capable of taking FP measurements (e.g., BMG 
Labtech POLARstar Omega).
 2. Appropriate wavelength filters for chosen fluorophore, one cor-
responding to excitation wavelength, and two (ideally a matched 
pair with identical optical properties), corresponding to the 
emission wavelength. Here, we use a 485 nm excitation filter 
and two matched 520 nm emission filters for fluorescein.
 3. Opaque, black, 384-well, non-binding, flat-bottom plates, 
either in standard format (e.g., 781,900, Greiner Bio-One) or 
in small-volume format (e.g., 784,900, Greiner Bio-One). The 
latter are particularly useful if limited protein is available.
 4. Microplate centrifuge (1000 × g, e.g., Beckman Coulter 
Allegra X-12R with SX4750 swinging bucket rotor, fitted with 
microplate inserts)
2.3 Fluorescence 
Polarization (FP) 
Assay
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 5. FP assay buffer: 25 mM HEPES–NaOH pH 7.5, 100 mM 
NaCl, 1 mM TCEP, 0.05% w/v 3-[(3-cholamidopropyl)
dimethylammonio]-1-propanesulfonate hydrate (CHAPS) 
(see Notes 7 and 11).
 6. Fluorescently tagged peptide corresponding to TBM of poten-
tial tankyrase binder/substrate, 2× stock (50 nM for a final 
assay concentration of 25 nM) in FP assay buffer. In the present 
examples (3BP2, MERIT40, TRF1), fluorescein and 5(6)-car-
boxyfluorescein are used as fluorophores. The peptides have 
been described previously [7]. We recommend peptides of min-
imally the TBM octapeptide with one flanking amino acid on 
either side. The peptides used here are longer (see Fig. 3b for 
peptide sequences). The fluorescein fluorophore is linked via 
β-Ala, which also provides an additional linker to minimize 
potential steric interference of the fluorophore with the pep-
tide-ARC interaction (see Note 8).
 7. Tankyrase ARC protein: 2× stock of twofold dilution series, 
0–400 μM, (final assay concentrations of 0–200 μM protein) in 
FP assay buffer.
 8. Software for curve fitting and analysis (e.g., GraphPad Prism 6).
 1. Mammalian expression constructs for epitope-tagged (e.g., 
MYC2) tankyrases (TNKS: NM_003747.2; TNKS2: 
NM_025235.2) and epitope-tagged (e.g., FLAG) tankyrase- 
binding protein candidates (here for TRF1/TERF1: 
NM_017489.2 and MERIT40/BABAM1: NM_001033549.2), 
corresponding empty vectors as controls.
 2. QuikChange Lightning mutagenesis kit (Agilent Technologies) 
or individual components from other sources for site- directed 
mutagenesis.
 3. Mutagenesis primers to mutate putative TBM (recommended 
mutation: G6R).
 4. PCR thermal cycler, standard setup and reagents for recombi-
nant DNA techniques.
 5. Human Embryonic Kidney (HEK) 293T cells (ATCC).
 6. 10 cm and 15 cm cell culture dishes.
 7. Hemocytometer or automated cell counter.
 8. Dulbecco’s Modified Eagle’s Medium (DMEM).
 9. Fetal bovine serum (FBS).
 10. Humidified cell culture incubators at 37 °C, 5% CO2.
 11. 0.2% Versene in PBS (137 mM NaCl, 2.7 mM KCl, 8 mM 
Na2HPO4, 1.5 mM KH2PO4, 537 μM EDTA, 80 μM phenol 
red, final pH adjusted to 7.2, sterilization-autoclaved; all 
reagents cell-culture grade).
2.4 Binding 
and PARylation 
of Full-Length 
Candidate Proteins 
by Tankyrase in Cells
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 12. 0.05% trypsin in Versene (137 mM NaCl, 2.7 mM KCl, 8 mM 
Na2HPO4, 5.5 mM d-glucose, 1.5 mM KH2PO4, 25 mM 
Tris, 1% phenol red, 0.5 g trypsin (1:250) per 1 L, 137 μM 
streptomycin sulfate, 168 μM benzyl penicillin, final pH 
adjusted to 7.5, filter-sterilized using a 0.22 μm filter).
 13. Ultra-filtered sterile H2O.
 14. Calcium phosphate transfection reagents (all cell culture grade):
 (a)  2× HEPES-buffered saline (HBS): 50 mM HEPES, 
10 mM KCl, 280 mM NaCl, 1.5 mM Na2HPO4, 12 mM 
glucose, final pH adjusted to 7.05 with KOH, filter-steril-
ized and stored at 4 °C.
 (b)  25 mM chloroquine diphosphate, filter-sterilized and 
stored at −20 °C (1000× stock).
 (c) 2 M CaCl2, filter-sterilized and stored at 4 °C.
 15. Phosphate-buffered saline (PBS).
 16. Cell scraper.
 17. Refrigerated centrifuge for collecting mammalian cells 
(300 × g, e.g., Beckmann Coulter Allegra X-12R with SX4750 
swinging bucket rotor).
 18. Radioimmunoprecipitation assay (RIPA) buffer: 50 mM 
HEPES–NaOH pH 7.5, 150 mM NaCl, 1% Triton X-100, 
0.5% sodium deoxycholate, 0.1% SDS, 1 mM DTT, 2 μM 
ADP-HPD PARG inhibitor and protease inhibitors (e.g., 
Pierce protease inhibitor tablets, EDTA-free, Thermo Fisher 
Scientific). Add DTT, ADP-HPD, and protease inhibitors 
immediately before use.
 19. Sonicator fitted with small probe.
 20. Refrigerated centrifuge for clearing lysates and settling affinity 
resin (800–18,000 × g, e.g., Eppendorf 5417R with F45-
30- 11 rotor).
 21. Anti-FLAG M2 Agarose resin.
 22. Vacuum pump with inlet trap and collection flask for aspirating 
buffer.
 23. SDS-PAGE gels (e.g., 4–15% Tris–glycine polyacrylamide gra-
dient gels for excellent resolution).
 24. Electrophoresis apparatus for the above and appropriate power 
supply.
 25. 4× SDS sample buffer.
 26. Protein standard for SDS-PAGE.
 27. Nitrocellulose transfer membrane.
 28. Wet transfer Western blotting apparatus and appropriate power 
supply.
 29. Ponceau S solution.
 30. Nonfat dry milk powder.
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 31. Mouse monoclonal anti-FLAG M2 HRP-conjugated antibody 
(here 1 mg/mL), mouse monoclonal anti-MYC (9E10) HRP-
conjugated antibody (here 1 mg/mL), rabbit polyclonal anti-
PAR (4336-BPC-100, Trevigen, concentration not specified by 
supplier), goat anti-rabbit IgG (H+L) secondary antibody, HRP- 
conjugate (here 0.8 mg/mL) (see Note 9).
 32. ECL Western blotting substrate.
 33. X-ray film for Western blot detection or alternative ECL detec-
tion setup.
3 Methods
The details of many standard experimental methods not addressed 
here can be found in [21].
Experimental approaches such as yeast-two-hybrid analysis [22] or 
co-immunoprecipitation coupled with tandem mass spectrometry 
[23] have been used to identify proteins present in complexes with 
tankyrase. It is desirable to pinpoint those proteins that directly 
interact with tankyrase. The existence of putative TBMs is the most 
reliable known indicator for direct interaction. Based on previously 
identified TBM sequence rules and structural information, we pro-
vide a guide to identifying strong TBM candidates for further vali-
dation. A previously generated list of ranked octapeptide motifs 
across the entire human proteome can be used [7]. Here, we reca-
pitulate a simple step-by-step approach for identifying candidate 
TBMs without the need for specialized bioinformatics beyond the 
use of established programs and databases.
 1. Screen your protein of interest for potential TBMs. In an initial 
step, a search for Arg and Gly spaced 6 amino acids apart (i.e., 
with four amino acids in between, RxxxxG) will suffice. See 
step 4 below for atypical TBMs.
 2. Using UniProt (http://www.uniprot.org), assess the topology 
of the protein and whether the candidate motif would be 
located in the cytoplasm or nucleoplasm, accessible to tankyrase 
[24]. The relevant information can be found under Subcellular 
location > Topology.
 3. Assess the occurrence of disordered stretches in your protein of 
interest. TBMs must be present in unstructured regions of the 
protein to be accessible to tankyrase and must not be part of a 
stable α-helix or β-strand. Secondary structure information, 
obtained from the Protein Data Bank [25], is available in UniProt 
(http://www.uniprot.org) under Structure > Secondary structure 
[24]. It remains possible that TBMs are present within loops of 
structured protein domains. If no structural information is avail-
able, a disorder predictor such as IUPred (http://iupred.enzim.
hu) may be used to obtain an indication of protein disorder [26].
3.1 Predicting 
Tankyrase Binders
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 4. Assess the short-listed sequences for their suitability as TBMs. 
REAGDGEE has been found to be the optimal 8-amino-acid 
TBM by positional scanning [7], but many TBMs only span six 
amino acids (positions 1–6). While the sequence rules from posi-
tional scanning prove valuable in predicting TBMs, it should be 
noted that some of their aspects may be specific to the context of 
the 3BP2 TBM peptide, which positional scanning was performed 
on [7]. Whereas Arg and Gly at positions 1 and 6, respectively, are 
essential, other residues are important as well, with the exception 
of positions 2 and 3, which can likely be ignored since they do not 
contribute to binding and mainly fulfil spacing roles (Fig. 1b, d). 
Please refer to the motif description under Subheading 1 for the 
assessment. Of note, a large or strongly charged amino acid at 
position 4 very likely disqualifies the TBM candidate as a genuine 
tankyrase binder. Furthermore, Asp and Glu at position 8 can 
compensate for unfavorable amino acids at other positions [7], as 
seen in one of the TBMs of AXIN1/2, where a suboptimal Val at 
position 4 appears to be counterbalanced by a Glu at position 8 
(Fig. 1e) [7, 11]. Interestingly, a second TBM in AXIN1/2 shows 
that the Arg, normally at position 1, can be placed further 
N-terminal, resulting in looping-out of the “inserted” residues 
(Fig. 1c, e). Likewise, the E3 ubiquitin ligase RNF146 has been 
proposed to contain numerous atypical TBMs with a nonconven-
tional positioning of the Arg [27], and it is possible that a distal 
Arg is required for weak binding of the TBM of GRB14 to 
tankyrase (Fig. 1e) [7, 8, 28]. Thus, the possibility of a distal Arg 
residue should be taken into consideration. It is likely that such 
extended TBMs display a weaker affinity for tankyrase. Numerous 
tankyrase binders contain multiple TBMs, such as AXIN1/2 [11] 
and MERIT40 [7] (see below). Since avidity effects likely contrib-
ute to binding of these proteins to tankyrase, the affinity of some 
of these individual TBMs for the ARC may be lower, and this may 
be reflected in deviations from the “optimal” sequence.
cDNA sequences encoding TNKS or TNKS2 ARC constructs are 
cloned into a pETM-30-2 expression vector (or similar vector) to gen-
erate fusion proteins with an N-terminal His6-GST tag followed by a 
TEV protease cleavage site (ENLYFQG) [7]. See Table 1 for sug-
gested ARC boundaries [7]. Chemically competent BL21-CodonPlus 
(DE3)-RIL E. coli cells for protein expression are transformed with 
sequence-validated plasmids. A single colony is selected to inoculate 
an overnight pre-culture, which is then used to inoculate the larger 
expression cultures (typically 4–8 L). The cultures are grown shaking 
at 37 °C to exponential phase, then cooled at 4 °C for 30 min before 
induction with IPTG overnight at 18 °C. The cells are then collected 
by centrifugation. Purification can either follow immediately, or cell 
pellets can be stored at −80 °C until processed for purification.
 1. Transform chemically competent BL21-CodonPlus (DE3)-RIL 
E. coli cells with tankyrase ARC expression constructs by heat 
3.2 Validating TBMs 
by Fluorescence 
Polarization (FP)
3.2.1 Expression 
of Tankyrase ARCs
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shock. Plate cells on LB agar plates containing suitable antibiotics, 
here kanamycin (50 μg/mL) and chloramphenicol (34 μg/mL) 
(see Notes 1 and 2). Incubate overnight at 37 °C.
 2. Pick a single colony from the plate and inoculate an overnight 
pre-culture of LB medium (100 mL) supplemented with 
50 μg/mL kanamycin and 34 μg/mL chloramphenicol. 
Incubate overnight in a shaking incubator at 37 °C.
 3. Add 5 mL of the pre-culture to each liter of TB medium sup-
plemented with 50 μg/mL kanamycin and 34 μg/mL chlor-
amphenicol. Generally, the yield for individual TNKS and 
TNKS2 ARC constructs is 6–10 mg/L of culture.
 4. Incubate cultures at 37 °C with shaking at 180 rpm until an 
optical density at 600 nm (OD600) of approximately 2.0 is 
reached. Remove cultures from incubator and cool them at 
4 °C for 30 min (see Note 10).
 5. Add IPTG to a final concentration of 0.5 mM (0.5 mL of 1 M 
stock per liter of culture) to induce protein production. 
Incubate cultures at 18 °C with shaking overnight (≈15 h).
 6. Collect cells by centrifugation in a precooled centrifuge at 4 °C 
for 30 min at 4000 × g.
 7. Discard supernatant. The cells can be lysed for immediate puri-
fication. Alternatively, pellets can be flash-frozen in a liquid 
nitrogen bath for storage at −80 °C until required.
A similar procedure is followed for the purification of all tankyrase 
ARCs. All buffers are ice-cold, and work is performed at 4 °C or 
on ice throughout. In the first step, the protein is affinity-purified 
by immobilized metal affinity chromatography (IMAC) using a 
Ni2+ affinity column. The affinity tag is then cleaved overnight 
using TEV protease, under simultaneous dialysis to remove imid-
azole from the elution step. A second Ni2+ affinity chromatogra-
phy step separates the cleaved tag from the protein. An optional 
anion exchange chromatography step removes further impurities. 
Finally, size exclusion chromatography yields high-quality purified 
protein for downstream applications. The general procedure is 
applicable to all TNKS and TNKS2 ARCs with small changes 
(Fig. 2a; see Note 11).
3.2.2 Purification 
of Tankyrase ARCs
Fig. 2 (continued) purification of His6-GST-TNKS2 ARC5 fusion protein. T, total lysate; S, soluble lysate; FT, 
flow-through; W, wash. (c) Removal of the His6-GST affinity tag by TEV cleavage and a second Ni2+ affinity 
purification step. Pre-TEV, protein before TEV cleavage; Post-TEV, protein after TEV cleavage; S, pooled 
protein after subtraction of affinity tag. (d) Anion exchange chromatography. Pre-Q, protein before anion 
exchange chromatography; Post-Q, protein after anion exchange chromatography. (e) Size exclusion chro-
matography. M, marker; I, input
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Fig. 2 Purification of tankyrase ARCs. (a) 5 μg purified TNKS and TNKS2 ARCs were resolved on 15% Tris–
glycine polyacrylamide gels for SDS-PAGE and the gels stained with Coomassie. M, marker. See Table 1 for 
construct boundaries. (b)-(e) Step-by-step purification of a representative ARC, TNKS2 ARC5. (b) Ni2+ affinity 
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 1. Dissolve protease inhibitor tablets in the required volume of 
lysis buffer (approximately 20 mL of buffer for every 10 g of 
cell pellet) and add lysozyme (100 μg/mL final) in a large glass 
beaker containing a magnetic stirrer bar. Add frozen cell pellet 
and stir gently until cells are completely thawed and a homo-
geneous suspension is obtained.
 2. Break cells by using a large-tip sonicator at 40% amplitude out-
put, using a 5 s on, 5 s off pulse, for a total of 5 min “on” time. 
Keep cells on ice continuously to avoid overheating (see Note 
12). Take a sample of the total lysate for subsequent analysis by 
SDS-PAGE (9 μL lysate + 3 μL 4× SDS sample buffer).
 3. Remove cell debris and insoluble material by centrifugation at 
30,000 × g for 30 min. If lysate is still cloudy, centrifuge for a 
further 30 min until clear.
 4. While the lysate is being cleared, prepare a 5 mL HisTrap Ni2+ 
affinity column by washing with 10 column volumes (CV) of 
H2O and then equilibrating with 10 CV of buffer A for Ni2+ 
affinity column, using a low-pressure peristaltic pump, set to a 
flow rate of 2 mL/min (see Note 3).
 5. Decant the supernatant into a beaker, and sonicate on ice, 5 s 
on, 5 s off for a total of 20 s “on” time to further break up 
genomic DNA and avoid clogging the filter in the next step.
 6. Filter the supernatant through 5.0 μm syringe filter units. Take 
a sample of the soluble lysate for subsequent analysis by SDS-
PAGE (9 μL lysate + 3 μL 4× SDS sample buffer). Load the 
cleared lysate on the equilibrated HisTrap column using the 
peristaltic pump as before (see Note 13). The His6-GST- tagged 
protein will bind to the immobilized Ni2+ ions. Wash the col-
umn with 20 CV of buffer A (100 mL) to remove unbound 
contaminants. Collect lysate flow-through and the wash buffer 
in case the protein was not bound or was released during the 
wash, and take samples for analysis by SDS-PAGE (9 μL flow-
through or wash + 3 μL 4× SDS sample buffer).
 7. Attach the HisTrap column to an FPLC system, and elute the 
His6-GST-ARC protein with the following three-step proto-
col, at a flow rate of 2 mL/min, collecting 1.5 mL fractions in 
a 96-deep-well block:
step 1: 100% buffer A for 2 CV.
step 2: gradient from 0–100% buffer B over 20 CV.
step 3: 100% buffer B for 4 CV.
 8. Take samples of each peak elution fraction (9 μL of elu-
ate + 3 μL 4× SDS sample buffer). Analyze the samples taken 
in steps 2 and 6 (2 μL of sample for lysates and flow-through, 
5 μL of sample for wash) and the peak elution fractions (5 μL 
of sample) by SDS-PAGE (Fig. 2b).
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 9. Pool fractions containing ARC fusion protein. Take a sample 
of the pooled fractions (9 μL of protein + 3 μL 4× SDS sample 
buffer). Add TEV protease (approximately 100 μL of 5 mg/
mL stock for every 25 mL fusion protein solution) to cleave 
the tag.
 10. Soak dialysis tubing (3500 Da MWCO) in dialysis buffer, and 
seal one end with a dialysis membrane clip. Transfer the pro-
tein into the dialysis tubing and seal the other end. More than 
one dialysis tube may be required. Dialyze overnight in a 2 L 
glass beaker containing dialysis buffer, with gentle stirring at 
4 °C. Avoid contact between the stirrer bar and the dialysis 
tubing to prevent rupture.
 11. Pour content of dialysis tubing into 50 mL Falcon tubes. 
Centrifuge at 3200 × g for 15 min to remove any precipitate 
that may have formed. Take a sample of the protein post-TEV 
cleavage (9 μL of protein + 3 μL 4× SDS sample buffer). White 
precipitate often forms overnight with the change to low-salt 
buffer. SDS-PAGE analysis of the precipitate reveals it to be 
enriched in a contaminant (not shown).
 12. Meanwhile, wash a 5 mL HisTrap column with 10 CV of H2O. 
Next, equilibrate the column in 10 CV of dialysis buffer. Filter 
the supernatant through a 0.22 μm syringe filter and load it 
onto the equilibrated HisTrap column using the low- pressure 
peristaltic pump. Collect the flow-through. The untagged 
ARC protein will pass through, while the cleaved tag (or resid-
ual His6-GST-ARC fusion protein) will be retained on the col-
umn (see Note 14). Wash with 2 CV of dialysis buffer to fully 
remove all ARC protein from the column, collecting the wash. 
Take samples of the flow-through and wash (9 μL of pro-
tein + 3 μL 4× SDS sample buffer).
 13. Analyze 5 μL of the pre-TEV sample, post-TEV sample and 
flow-through/wash samples from the second Ni2+ column by 
SDS-PAGE to assess successful tag removal and separation 
(Fig. 2c).
 14. Take the protein-containing samples (flow-through/wash) 
and concentrate the protein to about 20 mL by centrifuging in 
a 3000 Da MWCO spin concentrator at 3200 × g for 30 min 
at a time in a swinging bucket rotor. Mix by gently pipetting 
up and down to prevent a steep concentration gradient from 
forming in the concentrator. Take a sample of the concentrated 
protein (9 μL of protein + 3 μL 4× SDS sample buffer).
 15. The following anion exchange chromatography step is optional, 
but was found to increase the purity of ARC proteins, especially 
TNKS2 ARC5, by removing a higher-molecular- weight impu-
rity. Using the peristaltic pump at 2 mL/min, wash a 5 mL 
HiTrap Q HP column with 5 CV of H2O, followed by 5 CV of 
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buffer B for Q column, and then equilibrate with 10 CV of buf-
fer A for Q column. Pass the concentrated protein over the 
column, and collect the flow- through. Wash the column with 
2 CV of buffer A for Q column, also collecting the flow-
through. ARCs do not bind to the Q column; however, the 
impurity does and will be retained on the column (see Note 
15). Take a sample of the combined flow-through and wash 
(9 μL of protein + 3 μL 4× SDS sample buffer). Analyze 5 μL 
of the samples from step 14 and this step by SDS-PAGE as 
above (Fig. 2d).
 16. Concentrate the protein as in step 14, to ≤2 mL.
 17. Centrifuge protein in a microcentrifuge tube at 18,000 × g for 
10 min to remove any particles before size exclusion 
chromatography.
 18. Load the concentrated protein onto an equilibrated size exclu-
sion column connected to an FPLC system, using a 2 mL sam-
ple loop (see Note 4). Elute the protein isocratically, using 
1.2 CV of size exclusion buffer. Collect 1 mL fractions in a 
96-deep-well block.
 19. Take samples of the input material and peak fractions (9 μL 
input or fraction + 3 μL 4× SDS sample buffer). Analyze 5 μL 
of the samples by SDS-PAGE (Fig. 2e).
 20. Combine fractions containing pure protein. Wash the mem-
brane of a spin concentrator by spinning through one concen-
trator volume of H2O to remove any stabilizing agents such as 
glycerol and azide. Now concentrate the protein using the pre-
washed spin concentrator as described above (step 14) until a 
concentration of >0.5 mM is achieved (solubility of multi- 
ARC constructs can be lower). The concentration can be 
determined by measuring the UV absorbance at 280 nm and 
using the molar extinction coefficient calculated by ProtParam 
(http://web.expasy.org/protparam/) [29].
 21. Aliquot the protein into small volumes in thin-walled PCR 
tubes and flash-freeze them in a liquid nitrogen bath. Frozen 
protein aliquots can be stored at −80 °C until future use.
This assay measures the direct binding of a fluorescently labeled 
TBM candidate peptide to a tankyrase ARC [7]. The ARC protein 
is titrated at a constant peptide probe concentration, and the 
change in polarization (ΔFP) is measured and plotted. Plotting 
ΔFP values against [ARC] enables a dissociation constant (Kd) to 
be calculated. In the present example, we use fluorescein-based 
peptide labels, but the general method can be adapted for different 
fluorophores.
 1. Ensure the plate reader is set up for fluorescence polarization, 
with the correct filters for the fluorophore. The fluorescein 
3.2.3 Fluorescence 
Polarization Assay for TBM 
Validation
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example uses a 485 nm excitation filter and two 520 nm emis-
sion filters, one parallel and one perpendicular to the plane of 
the linearly polarized light used for excitation.
 2. Dissolve the lyophilized peptide probe in FP assay buffer, to 
approximately 100 μM. The concentration can be measured 
spectrophotometrically (see Note 16). Here, we measure the 
absorbance of the peptide stock at 492 nm and use a molar 
extinction coefficient for fluorescein of ε492 = 83,000/M/cm 
[30]. The concentrated probe can then be aliquoted into small 
volumes (5–10 μL) and flash-frozen in liquid nitrogen for 
long-term storage at −80 °C, to be thawed when required.
 3. Determine the optimal probe concentration to use. This will 
depend on the sensitivity of the plate reader. FP values should 
be independent of the probe concentration used, and give a 
robust signal window for an unbound vs. protein-bound pep-
tide. Make 2× stocks of a twofold dilution series of probe in FP 
buffer, from 0–800 nM (10 concentrations + no peptide). It is 
often easier to make a 1/100 dilution of the concentrated pep-
tide stock to avoid pipetting small volumes. Total sample vol-
umes per well are either 15 or 50 μL (see step 5 below).
 4. Prepare a 2× protein stock solution, by diluting tankyrase ARC 
protein in FP buffer to 20 μM (10 μM final protein concentra-
tion). The protein concentration should be in vast excess over 
the peptide probe to obtain a first impression of the anticipated 
signal window between free and protein-bound peptide probe.
 5. Plate out the assay samples in technical duplicate (see Table 2, 
Note 17). Small-volume plates will require 15 μL per well 
(7.5 μL of each stock), standard-volume plates 50 μL per well 
(25 μL of each stock). Mix the probe stock solution 1:1 with 
either FP buffer for the peptide probe-only titration or protein 
Table 2 
Example plate layout for establishing the probe concentration in a fluorescence polarization assay.
Rows B and C correspond to 3BP2 peptide titrations (here up to 400 nM) in the absence of protein, 
while rows D and E correspond to 3BP2 peptide titrations in the presence of protein. Numbers 
correspond to final fluorophore concentration (nM). Blank wells contain buffer alone. Standard wells 
contain 5 nM of free fluorescein. Wells along the edge of the microplate (row A and column 1) are left 
empty to minimize the “edge effect” (see Note 17)
1 2 3 4 5 6 7 8 9 10 11 12 13 14
A
B 0 0.78 1.56 3.13 6.25 12.5 25 50 100 200 400 Blank Standard
C 0 0.78 1.56 3.13 6.25 12.5 25 50 100 200 400 Blank Standard
D 0 0.78 1.56 3.13 6.25 12.5 25 50 100 200 400 Blank Standard
E 0 0.78 1.56 3.13 6.25 12.5 25 50 100 200 400 Blank Standard
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stock for the titration in the presence of protein. Add a “blank” 
well with FP buffer only. A well with 5 nM fluorescein  (literature 
FP of 35 millipolarization units, mP) can be used as a standard 
to automatically set the gain adjustment of the plate reader. 
Temporarily seal the plate with adhesive film or a lid and spin at 
1000 × g for 1 min in a swinging bucket rotor with plate inserts. 
Incubate in the dark at room temperature for 30 min to ensure 
binding equilibrium is reached.
 6. Set the gain adjustment of the instrument. The POLARstar 
Omega automatically calculates the gain by scaling the FP 
value to 35 mP for the wells containing 5 nM free fluorescein. 
50 flashes per well is a good starting point to minimize fluoro-
phore bleaching, and means each data point will be the average 
of 50 measurements.
 7. Read the plate and calculate FP in mP. Some plate readers and 
software packages will automatically blank-correct and calcu-
late the FP values. If not, subtract the averaged F_parallel and 
F_perpendicular readings obtained for the blank wells from the 
corresponding individual values of the other wells. FP values 
are calculated using the following equation:
FP mP
F parallel F perpendicular
F parallel F perpendicu
( ) = -( )
+
_ _
_ _ lar( ).
F_parallel and F_perpendicular denote the fluorescence inten-
sities parallel and perpendicular to the plane of the linearly 
polarized light used for excitation. mP, millipolarization units.
 8. Export the FP data and raw fluorescence intensity values. Plot 
the data (average FP vs. [probe]) using GraphPad Prism or 
your data analysis program of choice (Fig. 3a).
 9. Determine the minimum probe concentration required. Raw 
fluorescence intensity values of >10× the blank reading are 
necessary to calculate accurate FP values. In the example shown 
in Fig. 3a, fluorescence intensity values measured with probe 
concentrations below 6.25 nM were too low and therefore 
excluded.
 10. Determine the maximum probe concentration. The FP values 
will drop sharply when the signal overloads the detectors. In 
this case, both detectors reach saturation, so the fluorescence 
intensities registered in the parallel and perpendicular channels 
will be identical, and hence the FP calculated will be zero. In 
the example shown in Fig. 3a, 50 nM is the maximum usable 
peptide probe concentration. FP readings between 6.25 and 
50 nM probe are approximately constant.
 11. Peptide probe concentrations should be kept as low as reason-
ably possible. Thus, the peptide concentration can be ignored 
in Kd calculations. 25 nM probe was chosen for the protein 
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Fig. 3 Assessing ARC–TBM peptide interactions by fluorescence polarization. (a) Optimization of the peptide probe 
(3BP2) concentration for the FP binding assay. Data are from one experiment performed in technical duplicate with 
mean FP values plotted. The dashed vertical lines indicate the suitable peptide probe concentration range. 25 nM 
was chosen for the subsequent assays. (b) FP binding assays for the TBM peptides from TRF1, MERIT40, and 3BP2 
(WT positive control and G6R negative control). Peptide sequences (with octapeptide in bold) and affinities for TNKS2 
ARC5 are indicated. n = 3 separate experiments; error bars, SEM. The error values for the dissociation constants 
correspond to the standard error of the fit in nonlinear regression. n.d., not determined (no binding curve)
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titration experiments shown below. Prepare a 2× probe stock 
solution (50 nM in FP buffer). Prepare a twofold dilution 
series of tankyrase ARC protein from 0–400 μM (0–200 μM 
final concentration) in FP buffer. The maximum protein con-
centration may be lowered if Bmax is reached at low protein 
concentrations, i.e., in the case of high affinity. An initial maxi-
mum [ARC] of 200 μM ensures that binding can be detected 
for weak binders as well.
 12. Set up a binding experiment for Kd determination. Mix the 
probe and protein stock solution 1:1 to give a final well volume 
of 15 μL (7.5 μL of each stock solution, small-volume plates). 
Centrifuge the plate as in step 5 above. Incubate the plate in 
the dark at room temperature for 30 min to achieve equilib-
rium before measurement.
 13. Calculate FP as in step 7 above and export the raw fluores-
cence and calculated FP values.
 14. Enter the individual FP values into GraphPad Prism or your 
data analysis program of choice.
 15. Baseline-correct by subtracting the FP value for the zero- 
protein well from all other values in that row, to obtain ΔFP 
values. Calculate the mean of the technical duplicates. Plot 
ΔFP against [protein]. Perform a nonlinear regression analysis, 
using a one-site total binding model:
ΔFP = Bmax × [ARC]/(Kd + [ARC]) + NS × [ARC] + Back
ground
Bmax denotes the maximum specific binding in mP, where 
the binding curve saturates; Kd is the dissociation constant; 
NS denotes the slope of nonspecific binding in ΔFP/[ARC] 
units; Background denotes the baseline ΔFP value, which 
should be zero. Although it is possible to constrain the back-
ground to zero, it is advisable to retain the background term 
since the baseline is defined by more values than that from the 
zero-protein sample.
Non-binding peptides will give a straight line of nonspecific 
binding. Binding peptides will give a logarithmic curve 
(Fig. 3b). This analysis will yield a Kd value.
 16. Repeat the experiment to obtain pooled data from (typically 
three) separate experiments. In each separate experiment, 
technical duplicates are combined into a single data point. 
Error bars (SEM) are calculated for the mean data points 
from the separate experiments (Fig. 3b). The peptides from 
3BP2, TRF1, and MERIT40 (two peptides) bind TNKS2 
ARC5 with the indicated affinities, while no binding is 
detectable for the G6R negative control peptide from 3BP2 
(Fig. 3b).
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This final section outlines a step-by-step approach to assess and 
validate the full-length candidate protein interaction with full- 
length tankyrase and the extent of its tankyrase-dependent 
PARylation. Mammalian expression constructs for MYC2-tagged 
TNKS2 (pLP-dMYC SD-TNKS2) and FLAG- or FLAG3-tagged 
candidate interacting proteins (pCMV-FLAG-MERIT40 and 
pLP- tripleFLAG SD-TRF1) are generated. Standard site-directed 
mutagenesis is performed to mutate the Gly at position 6 of the 
FP-validated TBMs to Arg. The FLAG-tagged candidate proteins 
and corresponding TBM mutant derivatives are next used as 
“baits” in co-immunoprecipitation experiments, to assess their 
binding to and their PARylation by MYC2-TNKS2, using catalyti-
cally inactive TNKS2 (G1032W) as control [31].
 1. Grow a sufficient number (here two) 15 cm cell culture plates 
of HEK293T cells to a cell density of ≈90% confluence in stan-
dard DMEM media supplemented with 10% FBS.
 2. Remove the media and gently rinse the cell culture plates with 
10 mL of Versene to remove residual media, which could 
impede the efficient dissociation of the cells by trypsin.
 3. Add 3 mL of trypsin–Versene to each plate and place the plates 
back in the incubator for 2 min. Gently tap the side of the 
plates to help the cells detach from the plate and dissociate 
from each other.
 4. Add 10 mL of DMEM media with 10% FBS to each plate; the 
FBS will inactivate the trypsin. Pipette the cell suspension up 
and down a few times to ensure proper dissociation of cell 
clumps into a homogenous cell suspension.
 5. Measure the cell density, using either a hemocytometer or 
automated cell counter. Add 6 × 106 cells each to the 
required number of 10 cm cell culture plates for the co-
transfection of different DNA constructs (Table 3). Add 
10 mL of DMEM media with 10% FBS to each plate and 
incubate cells overnight.
 6. The next day, co-transfect cells with 5 μg of each DNA con-
struct (thus 10 μg total) per plate (Table 3). Pipette 5 μg of 
each DNA construct in a 15 mL Falcon tube, add 250 μL of 
2 M CaCl2 followed by 1.75 mL H2O and mix thoroughly. 
Subsequently, add 2 mL of 2× HBS, mix the solution thor-
oughly by pipetting up and down and incubate for 5–10 min 
at room temperature (see Note 18).
 7. Replace the growth media from the 10 cm plate with 15 mL of 
fresh growth media supplemented with 25 μM chloroquine. 
Chloroquine inhibits degradation of endocytosed DNA and 
can increase transfection efficiency [21].
 8. Gently add the transfection mix (4 mL each, dropwise) to each 
plate and incubate transfected cells for 24 h.
3.3 Validation 
of Tankyrase Binding 
and PARylation 
in Full-Length Protein 
Context
3.3.1 Co-expression 
of TNKS2 and MERIT40 or 
TRF1 in HEK293T Cells
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 9. The next day, remove the media and add 10 mL of ice-cold 
PBS. Harvest the cells by gently scraping them off the plate 
(see Note 19). Collect the scraped cell suspension in a 
15 mL Falcon tube and pellet the cells by centrifugation at 
300 × g for 5 min at 4 °C. Discard the supernatant; snap-
freeze cell pellet in liquid nitrogen and store at −80 °C until 
further use.
 1. Add 1 mL of ice-cold RIPA buffer (with freshly added DTT 
and protease inhibitors) to each cell pellet and resuspend cells 
on ice. The freeze–thaw and the detergents will break open the 
cells. Transfer the lysates to 1.5 mL microcentrifuge tubes and 
incubate on ice for 5 min for extraction.
 2. Sonicate lysates for 6 s on ice, using a small tip sonicator at 25% 
amplitude output to shear chromatin.
 3. Clear cell lysates by high-speed centrifugation at 18,000 × g for 
15 min at 4 °C and transfer supernatants to new 1.5 mL micro-
centrifuge tubes.
 4. Transfer 30 μL of each cleared lysate to a new microcentrifuge 
tube (input samples) and add 10 μL 4× SDS sample buffer. 
Boil samples at 95 °C for 5 min, collect by brief centrifugation, 
and store at −20 °C until analysis, if required.
 5. Pre-equilibrate a sufficient amount of anti-FLAG M2 Agarose 
resin (25 μL of packed-volume resin per immunoprecipitation 
sample plus a minimum of 10% dead volume) with RIPA buf-
fer and incubate resin with cleared lysates for 2 h on a rotating 
wheel at 4 °C.
 6. Gently settle the resin by centrifugation at 800 × g for 5 min at 
4 °C and remove supernatant using a vacuum pump.
3.3.2 Co-immuno-
precipitation
Table 3 
Chart for co-transfection of HEK293T cells for co-immunoprecipitation. The indicated FLAG/FLAG3- 
tagged constructs (5 μg) are used as baits in co-immunoprecipitation with the indicated MYC2-
tagged TNKS2 constructs (5 μg). The G-to-R mutation at position 6 of the TBM efficiently abolishes 
the ARC–TBM peptide interaction [7]. A G1032W mutation abolishes both poly- and mono(ADP-
ribosyl)ation by TNKS2 [31]. Each "+" sign denotes a single co-transfection setup
empty FLAG 
vector
MERIT40 
WT
MERIT40 
G33R
MERIT40 
G53R
MERIT40 
GG33/53RR TRF1 WT
TRF1 
G18R
empty MYC2 
vector
− + − − − + −
TNKS2 WT ++ + + + + + +
TNKS2 
G1032W
− + − − − + −
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 7. Wash the resin by adding 1 mL of RIPA buffer to each sample 
and incubating microcentrifuge tubes for 5 min on a rotating 
wheel at 4 °C.
 8. Settle the resin as before (step 6) and repeat the wash step four 
more times.
 9. After the last wash step, gently remove as much of buffer as 
possible and add 25 μL of 2× SDS sample buffer. Boil samples 
at 95 °C for 5 min, collect briefly by centrifugation and store 
at −20 °C until analysis, if required (immunoprecipitate (IP) 
samples).
 1. Resolve 10 μL of the boiled input (step 4 above) and IP (step 
9 above) samples on a pre-cast 4–15% Tris–glycine polyacryl-
amide gradient gel for SDS-PAGE analysis.
 2. Transfer proteins from the gel onto a nitrocellulose membrane 
using a wet-transfer blotting system. Ponceau S can be used to 
assess the transfer quality.
 3. Incubate the nitrocellulose membrane for at least 1 h at room 
temperature on a horizontal shaking platform in 5% dry milk 
powder in PBS to block the membrane to reduce nonspecific 
binding of antibodies during the subsequent immunodetec-
tion steps.
 4. Incubate the membranes with the required antibody at the 
appropriate dilution in 5% milk/PBS overnight at 4 °C on a 
horizontal shaking platform. (Antibody dilutions: anti-FLAG 
HRP-conjugated antibody, 1:1000; anti-MYC HRP-
conjugated antibody, 1:1000; anti-PAR, 1:1000).
 5. Wash the membrane three times for 5 min with copious 
amounts PBS + 0.1% Tween 20 on a horizontal shaking 
platform.
 6. As required, incubate the membrane with the matching HRP- 
coupled secondary antibody, here diluted 1:5000 in 5% milk/
PBS for 1 h at room temperature on a horizontal shaking plat-
form (see Note 20).
 7. Repeat wash step 5.
 8. Develop Western blot by incubating membrane with ECL 
Western blotting substrate following the manufacturer’s 
instructions.
 9. Detect chemiluminescence signal by exposing membrane to 
X-ray film in a dark room and develop the film with an X-ray 
film developer (see Note 21). Fig. 4 shows the TBM-
dependent interaction of FLAG3-TRF1 and FLAG-MERIT40 
with MYC2- TNKS2, and the TNKS2-dependent PARylation 
of both TNKS2 interactors, in addition to TNKS2 auto-
PARylation (see Note 22). Both MERIT40 TBMs contribute 
to tankyrase binding (Fig. 4b).
3.3.3 SDS-PAGE 
and Immunoblotting
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4 Notes
 1. We recommend using vectors with a kanamycin selection 
marker. Ampicillin hydrolysis by secreted β-lactamase and 
under low pH increases the proportion of cells lacking the plas-
mid, which decreases protein yield [33].
Fig. 4 Assessing tankyrase binding and PARylation by tankyrase in the full-length protein context. (a) FLAG3- 
TRF1, either in its wild-type form or as a G18R TBM mutant (“mut.”), was co-expressed with the indicated 
MYC2-TNKS2 constructs, either in wild-type form or as a G1032W PARP-inactive mutant (“GW”) [31]. FLAG- 
TRF1 was immunoprecipitated and input and immunoprecipitate (IP) samples analyzed by SDS-PAGE and 
Western blotting as indicated. “•” in the anti-PAR blot labels a high-molecular-weight PARylated species that 
appears to be antagonized by MYC2-TNKS2 overexpression. “*” in the anti-PAR blot denotes a nonspecific 
band. (b) Same analysis as in (a) with FLAG-MERIT40, either in wild-type form or as a G33R (“mut. 1”), G53R 
(“mut. 2”), or GG33/53RR (“mut. 1 + 2”) TBM mutant. MERIT40 appears as a doublet, most likely reflecting 
differentially phosphorylated species [32]. See Note 22 on attributing PAR signals to candidate proteins
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 2. RIL cells contain additional tRNAs for codons of Arg, Ile, and 
Leu that are otherwise rare in E. coli. The plasmid bearing 
these genes contains a chloramphenicol selection marker.
 3. We recommend using one 5 mL column per 4 L expression 
culture. If using larger volumes, connect additional column(s) 
in series. Ni2+ affinity columns can easily be reconstituted by 
stripping from and re-charging with Ni2+ as per the manufac-
turer’s instructions.
 4. Use a Superdex 200 column for ARC1-5 constructs. All other 
ARC constructs are sufficiently small for the Superdex 75 
column.
 5. TCEP is more stable than DTT and not volatile, unlike 
β-mercaptoethanol or DTT. However, TCEP is acidic and will 
affect the final pH of the buffer unless the 0.5 mM stock solu-
tion is pH-adjusted with NaOH. To keep costs down, TCEP is 
only used in the final purification step.
 6. HEPES is preferred for the final protein and in experiments 
due to its lower temperature dependency compared with Tris 
[34]. Tris was chosen for the affinity purification step due to its 
weak interaction with Ni2+, which would help decrease back-
ground (contaminant) binding [35]. If HEPES buffer is used 
in the affinity purification step, the imidazole concentration 
may need to be increased to achieve comparably low back-
ground binding.
 7. Detergent is used to reduce nonspecific binding and surface ten-
sion that may interfere with fluorescence intensity readings in 
the plate format. The choice of detergent and its concentration 
is empirical. We have also had good experience with using 
100 μg/mL bovine serum albumin (BSA), but use CHAPS here 
since it is more effective at reducing nonspecific binding.
 8. Keeping the fluorescently labeled peptides as short as possible 
increases the ΔFP signal window between the bound and unbound 
states. Ideally, peptides should be HPLC-purified; however, this is 
not always realistically achievable, especially if large numbers of 
peptides are to be compared and no access to in-house solid-state 
peptide synthesis is available. To save costs, peptides can be used at 
non-HPLC-purified grade, in which case a capping step is strongly 
recommended after each amino acid coupling reaction to prevent 
peptide synthesis intermediates from being linked to the fluoro-
phore in the final coupling step and affecting the assay [7].
 9. Alternatively, fluorescently labeled antibodies can be used for 
detection with appropriate fluorescence imaging systems. 
Instead of the anti-PAR antibody, an anti-pan-ADP-ribose or 
anti-poly(ADP-ribose) binding reagents (MABE1016 and 
MABE1032, respectively, Millipore) may be explored.
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 10. Compared to LB, TB is richer and enables higher cell densities 
in the log phase of growth. Cooling the cultures before IPTG 
induction slows down expression, thereby facilitating correct 
protein folding and increasing protein solubility.
 11. For ARC2-3 and ARC1-5 constructs described here, a mini-
mal NaCl concentration of 300 mM needs to be maintained, 
compared to 100 mM for all single-ARC constructs, and glyc-
erol may further help stabilize the protein [7].
 12. For large volumes, it may be easier to lyse cells in two batches. 
Alternative disruption techniques can be used, such as homog-
enization by an Avestin EmulsiFlex homogenizer.
 13. If available with the FPLC setup, a superloop or, preferably, a 
sample pump can be used to load the column.
 14. Depending on the ARC construct and the final concentration 
of imidazole in the dialysis buffer, ARCs can bind weakly to the 
Ni2+ column even after tag cleavage. They can be eluted with a 
further imidazole gradient. While this adds one more step to 
the purification protocol, it enables even higher purities to be 
achieved.
 15. The Q column step can also be performed before concentra-
tion, directly using the flow-through from the second Ni2+ 
affinity column; however, prior concentration saves time in 
loading the column.
 16. Confirm the pH of the peptide stock solution before measur-
ing the concentration. Acidity, for example due to residual tri-
fluoroacetic acid from the peptide synthesis, will strongly affect 
fluorophore absorption.
 17. We recommend leaving wells in the outermost rows and col-
umns empty to reduce the microplate “edge effect,” a discrep-
ancy in readings between the central and peripheral wells [36].
 18. It is important to add the different transfection reagents in the 
specified order to ensure proper calcium phosphate–DNA par-
ticle formation.
 19. Avoid using micropipette tips to transfer the cell suspension 
after scraping. The small opening of the tips can cause cells 
to break due to shearing. You can cut off the tips to avoid 
this risk.
 20. For directly HRP-coupled antibodies, azide as a preservative 
should be avoided as it inhibits HRP activity.
 21. The Western blot protocol can be adapted for film-free chemi-
luminescence detection or fluorescence-based detection.
 22. Attributing a PAR signal to a particular protein by molecular 
weight may be challenging, in part due to possible PAR-induced 
mobility shifts in SDS-PAGE. Since the tankyrase substrate can-
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didates are immunoprecipitated from cell lysates, it is possible 
that the observed PAR signal corresponds to other PARylated 
proteins in a protein complex. Ultimate confirmation of sub-
strates can be obtained from experiments with purified proteins 
or PAR site mapping by mass spectrometry, for example.
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